Xeris Biopharma - XERS Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xeris Biopharma stock.
View analyst ratings for Xeris Biopharma or view top-rated stocks.

4 Wall Street research analysts have issued 12-month price targets for Xeris Biopharma's shares. Their XERS stock forecasts range from $6.00 to $6.50. On average, they predict Xeris Biopharma's stock price to reach $6.13 in the next year. This suggests a possible upside of 266.8% from the stock's current price.
View analysts' price targets for Xeris Biopharma or view top-rated stocks among Wall Street analysts.

Xeris Biopharma's stock was trading at $2.93 at the start of the year. Since then, XERS shares have decreased by 43.0% and is now trading at $1.67.
View the best growth stocks for 2022 here.

Xeris Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Xeris Biopharma.

Xeris Biopharma will be holding an earnings conference call on Wednesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "562978".

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its earnings results on Wednesday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The company had revenue of $22.07 million for the quarter, compared to analyst estimates of $22.92 million. Xeris Biopharma had a negative net margin of 217.81% and a negative trailing twelve-month return on equity of 258.57%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (0.30%), Sinecera Capital LLC (0.19%), AE Wealth Management LLC (0.06%), GPS Wealth Strategies Group LLC (0.05%), ProShare Advisors LLC (0.02%) and Simplex Trading LLC (0.00%). Company insiders that own Xeris Biopharma stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends for Xeris Biopharma.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XERS stock can currently be purchased for approximately $1.67.

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $226.34 million and generates $49.59 million in revenue each year. The company earns $-122,720,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

Xeris Biopharma employs 294 workers across the globe.

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for Xeris Biopharma is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.